Investors

Company Overview

We are a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, currently focused on type 2 diabetes. Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time.

Poxel's innovative pipeline of first-in-class products with disease-modifying mechanisms of action offers the potential for safer and more effective therapies for type 2 diabetes. Our lead compound, Imeglimin, has successfully completed Phase 2 clinical development for type 2 diabetes in the U.S. and EU. The Phase 3 TIMES program is currently underway in Japan.

Inception date: 2009
Employees: 30
Stock market: Euronext Paris - Compartment B
Ticker: POXEL
ISIN code: FR0012432516
First day of trading: February 6, 2015 (on Euronext)
Number of Shares Outstanding: 24,558,827

Contact Information

Investor Relations

Jonae Barnes
Senior Vice President, Investor Relations and Public Relations
T: +1 617-818-2985
Jonae.barnes@poxelpharma.com

Trophic Communications
Gretchen Schweitzer / Stephanie May
T: +49 89 238 877 34 or +49 171 185 56 82
may@trophic.eu

NewCap
Alexia Faure / Nicolas Merigeau
T: +33 1 44 71 94 94
poxel@newcap.eu

Sign up for email alerts

Be the first to receive breaking news

Sign up today